LATITUDE-PsA-3001
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naïve to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001)
- Sex: Any
- Age: Adult (18 - 64), Older Adult (65+)
- Accepting Healthy People: No
- Type: Interventional / Therapeutic
- Trial Phase: Phase III
- Conditions Being Studied:
Study Purpose
This study is being done to help answer the following questions: • How safe is zasocitinib and what are the side effects that might be related to it? • How does your psoriatic arthritis respond to zasocitinib? • What is the dose of zasocitinib most appropriate for patients with psoriatic arthritis? • How does zasocitinib compare to apremilast and placebo? Apremilast is an approved medication for psoriatic arthritis. A placebo is a treatment that looks exactly like the real study drug but has no active medication in it.
Who Can Participate
Age: 18 years and older
Locations
UH Cleveland Medical Center
11100 Euclid Ave
Cleveland OH, 44106
- UH IRB: STUDY20241495
- StudyID: 2024-01593
- ClinicalTrials.gov: NCT06671483
Questions or concerns? We're here to help.
Non-cancer Trials: 1-833-78TRIAL or Contact Us Online
Cancer Trials: 1-800-641-2422